{"brief_title": "ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.", "brief_summary": "This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.", "condition": ["Hepatitis C, Chronic"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Copegus", "Copegus", "peginterferon alfa-2a [Pegasys]", "peginterferon alfa-2a [Pegasys]"], "description": ["400mg po bid for 16 weeks", "400mg po bid for 24 weeks", "180 micrograms sc weekly for 16 weeks", "180 micrograms sc weekly for 24 weeks"], "arm_group_label": ["1", "2", "1", "2"], "criteria": "Inclusion Criteria: - patients >=18 years of age; - CHC infection (genotype 2 or 3); - liver biopsy (in <24 calendar months of first dose), with results consistent with CHC infection; - use of 2 forms of contraception during study and 6 months after the study in both men and women. Exclusion Criteria: - women who are pregnant or breastfeeding; - male partners of women who are pregnant; - conditions associated with decompensated liver disease; - other forms of liver disease, including liver cancer; - human immunodeficiency virus infection; - previous treatment with an IFN, pegylated IFN, ribavirin, viramidine, levovirin, or amantadine.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis C", "Hepatitis, Chronic", "Hepatitis C, Chronic", "Interferons", "Ribavirin", "Peginterferon alfa-2a", "Interferon-alpha"], "id": "NCT00077636"}